Switzerland· 66022001

Besponsa

A inotuzumab ozogamicin product containing inotuzumabum ozogamicinum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FB01

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedBesponsaATCL01FB01REGISTER NO.66022001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Inotuzumab ozogamicin is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FB01 (inotuzumab ozogamicin), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Inotuzumab ozogamicin · ATC L01FB01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of inotuzumab ozogamicin costs, country by country.

Normalised to the WHO defined daily dose (0.1 mg), so markets compare like for like.

  • Switzerland: $1418.36 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Inotuzumab ozogamicin · price per daily dose (0.1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1418.36
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
inotuzumabum ozogamicinum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01FB01
ATC class
Inotuzumab ozogamicin
Defined daily dose
0.1 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680660220012
    Durchstf 1 Stk
    CHF 11762.85

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

362 interactions on record for inotuzumab ozogamicin.

Graded by severity as the source publishes them — 96 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Inotuzumab ozogamicin · interactions on record

362 records

  • 96 severe
  • 263 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Inotuzumab ozogamicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inotuzumab ozogamicin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Besponsa
  • Liechtenstein · Besponsa
  • Norway · Besponsa

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4391beab-9222-4dda-9213-247f20adf5f2
GET /v1/drugs/4391beab-9222-4dda-9213-247f20adf5f2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "inotuzumabum ozogamicinum 1 mg",
  "valid_from": "2021-02-01",
  "limitations": "[{\"description\":\"BESPONSA wird nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes zur Behandlung von erwachsenen Patienten mit CD22-positiver, rezidivierender oder refraktärer B-Vorläuferzellen-ALL (akute lymphoblastische Leukämie) eingesetzt. Erwachsene Patienten mit Philadelphia Chromosom positiver (Ph+) rezidivierender oder refraktärer B-Vorläuferzellen-ALL sollten Therapieversagen bei einer Vorbehandlung mit mindestens einem Tyrosin Kinase Inhibitor (TKI) gezeigt haben. Eine Behandlung mit BESPONSA soll an spezialisierten hämatologischen Zentren erfolgen, welche die Infrastruktur, die Fachkenntnisse und die Erfahrung im Management von ALL-Patienten aufweisen.<br>\\n<br>\\nBESPONSA kann bei Patienten, bei denen keine Transplantation von hämatopoetischen Stammzellen (HSCT) folgt, für maximal 6 Zyklen eingesetzt werden, wird jedoch für maximal 3 Zyklen vergütet. Patienten, bei denen eine HSCT folgt, können während 2 Zyklen behandelt werden. Ein dritter Zyklus kann für Patienten in Betracht gezogen werden, die nach zwei Zyklen keine komplette Remission (CR) oder komplette Remission mit inkompletter hämatologischer Regeneration (CRi) mit minimaler Resterkrankungs- (MRD) Negativität erreicht haben.<br>\\n<br>\\nMuss BESPONSA für mehr als 3 Zyklen eingesetzt werden, vergütet die Pfizer AG im Rahmen einer Behandlung mit BESPONSA nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, ab dem 4. Zyklus resp. ab der 11. Packung BESPONSA den Fabrikabgabepreis an den Krankenversicherer zurück. Die Mehrwertsteuer kann nicht zusätzlich zu den Rückvergütungsbeträgen zurückgefordert werden. Die Aufforderung zur Rückvergütung soll innerhalb von 6 Monaten nach Verabreichung erfolgen.<br>\\n\",\"costApproval\":null,\"indication\":\"20696.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2021-02-01\",\"validTo\":null}]",
  "galenic_form": "Trockensub 1 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2018-02-01",
  "self_retention_pct": 10
}

See everything about inotuzumab ozogamicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.